Please login to the form below

Not currently logged in
Email:
Password:

Sutro

This page shows the latest Sutro news and features for those working in and with pharma, biotech and healthcare.

Celgene steps back from $1bn Sutro acquisition

Celgene steps back from $1bn Sutro acquisition

Celgene has the right to buy additional shares in Sutro on top of its current 15% stake, with an upper limit, but can no longer buy it outright. ... Sutro will get an undisclosed payment upon signing of the revised agreement and continues to be entitled

Latest news

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    1, 150. Sutro Biopharma/Celgene. Licence plus option to acquire Sutro. For development of multispecific antibodies and antibody drug conjugates (ADCs).

  • Pharma deals during October 2014 Pharma deals during October 2014

    Sutro receives an upfront of $95m with a further $90m in additional payments. ... Options also feature in the Celgene/Sutro deal and Roche/Heidelberg as noted above.

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    300. Sutro / Merck KGaA. Licence and collaboration. Sutro's antibody drug conjugate technology for oncology.

  • Pharma deals during September 2014 Pharma deals during September 2014

    Boehringer Ingelheim has taken a licence to Curevac's messenger RNA vaccine for one of its compounds and the Californian company, Sutro, has signed an early stage deal with Merck KGaA

  • Pharma deals during December 2012 Pharma deals during December 2012

    Sutro, based in California, is coy about the upfront referring to it as “substantial”. ... 510. Sutro / Celgene. Development and manufacture. Design and development of antibody drug conjugates.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • V Bryan Lawlis joins board of KaloBios V Bryan Lawlis joins board of KaloBios

    Dr Lawlis is current president and CEO of Itero Biopharmaceuticals and is a director at several other life sciences companies including Biomarin Pharmaceutical, Geron, and Sutro Biopharmaceuticals.

  • Sutro Biopharma hires chief business officer and VP research Sutro Biopharma hires chief business officer and VP research

    Sutro Biopharma has appointed Dr Jeremy Bender as chief business officer and Dr Aaron Sato as VP, research, as it prepares to advance development of its cancer antibodies. ... Dr Sato joins Sutro from OncoMed Pharmaceuticals, where he served as senior

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics